Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities - The REPRESENT Study Will Create One of the Most Diverse and Comprehensive Clinico-genomic Datasets to Uncover and Address Disparities in Cancer Care - Sema4’s Chief Medical Science Officer Will...

Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its Market Access...